# Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

> **NCT04047420** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 23 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TAF/EVG Insert

## Key facts

- **NCT ID:** NCT04047420
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-11
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-04-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047420, "Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04047420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*